Adult Acute Lymphoblastic Leukemia: Concepts and Strategies

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2010 Jan 27

PMID 20101737

Citations 95

Authors

Stefan Faderl

Susan OBrien

Ching-Hon Pui

Wendy Stock

Meir Wetzler

Dieter Hoelzer

Hagop M Kantarjian

Affiliations

Soon will be listed here.

Abstract

Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued. Although ALL is a success story in pediatric oncology, results in adults lag behind those in children. An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy. For this review, the authors summarized pertinent and recent literature on ALL biology and therapy, and they discuss current strategies and potential implications of novel approaches to the management of adult ALL. Cancer 2010. (c) 2010 American Cancer Society.

Citing Articles

Stattic suppresses p‑STAT3 and induces cell death in T‑cell acute lymphoblastic leukemia.

Li C, Chen H, Yen J, Yu S, Chou T, Yeh S Mol Med Rep. 2024; 31(2).

PMID: 39670305 PMC: 11653168. DOI: 10.3892/mmr.2024.13416.

The Validation of Digital PCR-Based Minimal Residual Disease Detection for the Common Mutations in IDH1 and IDH2 Genes in Patients with Acute Myeloid Leukemia.

Di J, Sheng T, Arora R, Stocks-Candelaria J, Wei S, Lutz C J Mol Diagn. 2024; 27(2):100-108.

PMID: 39615653 PMC: 11816622. DOI: 10.1016/j.jmoldx.2024.11.002.

Enhancement of the Sensitivity of the Acute Lymphoblastic Leukemia Cells to ABT-737 by Formononetin.

Abbasi Y, Pooladi M, Nazmabadi R, Amri J, Abbasi H, Aghabeygi R Int J Mol Cell Med. 2024; 13(3):259-271.

PMID: 39493513 PMC: 11530950. DOI: 10.22088/IJMCM.BUMS.13.3.259.

A dual role for PSIP1/LEDGF in T cell acute lymphoblastic leukemia.

Demoen L, Matthijssens F, Reunes L, Palhais B, Lintermans B, TSas S Sci Adv. 2024; 10(44):eado6765.

PMID: 39485844 PMC: 11529709. DOI: 10.1126/sciadv.ado6765.

Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.

Olejarz W, Sadowski K, Szulczyk D, Basak G Int J Mol Sci. 2024; 25(14).

PMID: 39062986 PMC: 11276786. DOI: 10.3390/ijms25147743.

References

Sebban C, Lepage E, Vernant J, Gluckman E, Attal M, Reiffers J . Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1994; 12(12):2580-7. DOI: 10.1200/JCO.1994.12.12.2580. View

de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S . Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2006; 109(4):1408-13. DOI: 10.1182/blood-2006-03-011908. View

Boissel N, Auclerc M, Lheritier V, Perel Y, Thomas X, Leblanc T . Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21(5):774-80. DOI: 10.1200/JCO.2003.02.053. View

Roman-Gomez J, Agirre X, Jimenez-Velasco A, Arqueros V, Vilas-Zornoza A, Rodriguez-Otero P . Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol. 2009; 27(8):1316-22. DOI: 10.1200/JCO.2008.19.3441. View

Larson R . Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant. 2009; 15(1 Suppl):11-6. DOI: 10.1016/j.bbmt.2008.11.018. View

Pui C, Rubnitz J, Hancock M, Downing J, Raimondi S, Rivera G . Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998; 16(12):3768-73. DOI: 10.1200/JCO.1998.16.12.3768. View

Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P . Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant. 2005; 36(8):683-9. DOI: 10.1038/sj.bmt.1705123. View

Marks D, Aversa F, Lazarus H . Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options. Bone Marrow Transplant. 2006; 38(7):467-75. DOI: 10.1038/sj.bmt.1705464. View

Fielding A, Richards S, Chopra R, Lazarus H, Litzow M, Buck G . Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2006; 109(3):944-50. DOI: 10.1182/blood-2006-05-018192. View

10.

OBrien S, Thomas D, Ravandi F, Faderl S, Pierce S, Kantarjian H . Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008; 113(8):2097-101. PMC: 4199453. DOI: 10.1002/cncr.23819. View

11.

Campana D . Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2008; 46(1):100-6. PMC: 2632881. DOI: 10.1053/j.seminhematol.2008.09.001. View

12.

Fielding A, Goldstone A . Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia. Bone Marrow Transplant. 2007; 41(5):447-53. DOI: 10.1038/sj.bmt.1705904. View

13.

Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F . Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche.... Blood. 2007; 109(9):3676-8. DOI: 10.1182/blood-2006-10-052746. View

14.

Rocha J, Cheng C, Liu W, Kishi S, Das S, Cook E . Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005; 105(12):4752-8. PMC: 1895006. DOI: 10.1182/blood-2004-11-4544. View

15.

Pui C, Relling M, Evans W . Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2003; 15(4):741-56. DOI: 10.1053/beha.2002.0225. View

16.

Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E . Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009; 27(6):911-8. DOI: 10.1200/JCO.2008.18.6916. View

17.

Healy J, Belanger H, Beaulieu P, Lariviere M, Labuda D, Sinnett D . Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. Blood. 2006; 109(2):683-92. DOI: 10.1182/blood-2006-02-003236. View

18.

Relling M, Dervieux T . Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2002; 1(2):99-108. DOI: 10.1038/35101056. View

19.

Lazarus H, Richards S, Chopra R, Litzow M, Burnett A, Wiernik P . Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006; 108(2):465-72. PMC: 1895498. DOI: 10.1182/blood-2005-11-4666. View

20.

Durrant I, Richards S, Prentice H, Goldstone A . The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001; 14(6):1327-52. DOI: 10.1016/s0889-8588(05)70189-1. View